Initial chemotherapy followed by surgical cytoreduction for the treatment of stage III/IV epithelial ovarian cancer

American Journal of Obstetrics and Gynecology

Volumn 195, Issue 2, 2006, Pages 568-574

  Everett, Elise N ^a   French, Amy E ^a   Stone, Rebecca L ^a   Pastore, Lisa M ^a   Jazaeri, Amir A ^a   Andersen, Willie A ^a   Taylor Jr , Peyton T ^a  

^a UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

Author keywords

Cytoreduction; Neoadjuvant chemotherapy; Ovarian cancer

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; ETOPOSIDE; PLATINUM DERIVATIVE; TAXANE DERIVATIVE;

ADULT; ADVANCED CANCER; ARTICLE; CANCER CHEMOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; CYTOREDUCTIVE SURGERY; DISEASE SEVERITY; EPITHELIAL OVARY CANCER; EVALUATION; FEMALE; HUMAN; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MEDICAL RECORD; MORBIDITY; OVARY CARCINOMA; PRIORITY JOURNAL; RETROSPECTIVE STUDY; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS; CHEMOTHERAPY, ADJUVANT; COMORBIDITY; CYSTADENOCARCINOMA; CYSTADENOCARCINOMA, MUCINOUS; CYSTADENOCARCINOMA, SEROUS; DISEASE PROGRESSION; FEMALE; HUMANS; MIDDLE AGED; MORBIDITY; NEOPLASM STAGING; OVARIAN NEOPLASMS; OVARY; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS;

EID: 33746481520     PISSN: 00029378     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ajog.2006.03.075     Document Type: Article

References (24)

1. Jemal A., Murray T., Ward E., Samuels A., Tiwari R.C., Ghafoor A., et al. Cancer statistics, 2005. CA Cancer J Clin 55 (2005) 10-30
2. Pecorrelli S, Creasman WT, Pettersson F, Benedet JL, Shaperd JH, editors. FIGO annual report on the results of treatment in gynecologic cancer. J Epidemiol Biostat 1998;3:75-102.
3. Bristow R.E., Tomacruz R.S., Armstrong D.K., Trimble E.L., and Montz F.J. Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J Clin Oncol 20 (2002) 1248-1259
4. Griffiths C.T., Parker L.M., and Fuller Jr. A.F. Role of cytoreductive surgical treatment in the management of advanced ovarian cancer. Cancer Treat Rep 63 (1979) 235-240
5. Hoskins W.J., McGuire W.P., Brady M.F., Homesley H.D., Creasman W.T., Berman M., et al. The effect of diameter of largest residual disease on survival after primary cytoreductive surgery in patients with suboptimal residual epithelial ovarian carcinoma. Am J Obstet Gynecol 170 (1994) 974-979
6. Le T., Krepart G.V., Lotocki R.J., and Heywood M.S. Does debulking surgery improve survival in biologically aggressive ovarian carcinoma?. Gynecol Oncol 67 (1997) 208-214
7. Eisenkop S.M., Friedman R.L., and Wang H.J. Complete cytoreductive surgery is feasible and maximizes survival in patients with advanced epithelial ovarian cancer: a prospective study. Gynecol Oncol 69 (1998) 103-108
8. Chen S.S., and Bochner R. Assessment of morbidity and mortality in primary cytoreductive surgery for advanced ovarian carcinoma. Gynecol Oncol 20 (1985) 190-195
9. Heintz A.P., Hacker N.F., Berek J.S., Rose T.P., Munoz A.K., and Lagasse L.D. Cytoreductive surgery in ovarian carcinoma: feasibility and morbidity. Obstet Gynecol 67 (1986) 783-788
10. Venesmaa P., and Ylikorkala O. Morbidity and mortality associated with primary and repeat operations for ovarian cancer. Obstet Gynecol 79 (1992) 168-172
11. Schwartz P.E. Neoadjuvant chemotherapy for the management of ovarian cancer. Best Pract Res Clin Obstet Gynaecol 16 (2002) 585-596
12. Ushijima K., Ota S., Komai K., Matsuo G., Motoshima S., Honda S., et al. Clinical assessment of neoadjuvant chemotherapy and interval cytoreductive surgery for unresectable advanced ovarian cancer. Int Surg 87 (2002) 185-190
13. Vrscaj M.U., and Rakar S. Neoadjuvant chemotherapy for advanced epithelial ovarian carcinoma: a retrospective case-control study. Eur J Gynaecol Oncol 23 (2002) 405-410
14. Kayikciog F., Kose M.F., Boran N., Caliskan E., and Tulanay G. Neoadjuvant chemotherapy or primary surgery in advanced epithelial ovarian carcinoma. Int J Gynecol Cancer 11 (2001) 466-470
15. Kuhn W., Rutke S., Spathe K., Schmalfeldt B., Florack G., von Hundelshausen B., et al. Neoadjuvant chemotherapy followed by tumor debulking prolongs survival in patients with poor prognosis in International Federation of Gynecology and Obstetrics Stage IIIC ovarian carcinoma. Cancer 92 (2001) 2585-2591
16. Vergote I.B., De Wever I., Decloedt J., Tjalma W., Van Gramberen M., and van Dam P. Neoadjuvant chemotherapy versus primary debulking surgery in advanced ovarian cancer. Semin Oncol 27 suppl (2000) 31-36
17. Griffiths C.T., Grogan R.H., and Hall T.C. Advanced ovarian cancer: primary treatment with surgery, radiotherapy, and chemotherapy. Cancer 29 (1972) 1-7
18. Griffiths C.T., Parker L.M., Lee S., and Finkler N.J. The effect of residual mass size on response to chemotherapy after surgical cytoreduction for advanced ovarian cancer: long-term results. Int J Gynecol Cancer 12 (2002) 323-331
19. Allen D.G., Heintz A.P., and Touw F.W. A meta-analysis of residual disease and survival in stage III and IV carcinoma of the ovary. Eur J Gynaecol Oncol 16 (1995) 349-356
20. Griffiths C.T. Surgical resection of tumor bulk in the primary treatment of ovarian carcinoma. Natl Cancer Inst Monogr 42 (1975) 101-104
21. Ozols R.F., Rubin S.C., Thomas G.M., and Robboy S.J. Epithelial ovarian cancer. In: Hoskins W.J., Perez C.A., Young R.C., Barakat R.R., Markman M., and Randall M.E. (Eds). Principles and practice of gynecologic oncology. 4th ed. (2004), Lippincott: Williams & Wilkins, Philadelphia 934-935
22. Schwartz P.E., Rutherford T.J., Chambers J.T., Kohorn E.I., and Thiel R.P. Neoadjuvant chemotherapy for advanced ovarian cancer: long-term survival. Gynecol Oncol 72 (1999) 93-99
23. Vergote I., De Wever I., Tjalma W., Van Gramberen M., Decloedt J., and van Dam P. Neoadjuvant chemotherapy or primary debulking surgery in advanced ovarian carcinoma: a retrospective analysis of 285 patients. Gynecol Oncol 71 (1998) 431-436
24. Ansquer Y., Leblanc E., Clough K., Morice P., Dauplat J., Mathevet P., et al. Neoadjuvant chemotherapy for unresectable ovarian carcinoma: a French multicenter study. Cancer 91 (2001) 2329-2334